NMRA

Neumora Therapeutics, Inc.

NMRA.US neumoratx.com
1.14
-0.06 (-5.00%)
USD · NASDAQ
52-week range
0.83
3.65
Trading at 11% of the 52-week range
Market Cap
214.20M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
0.24
Div. Yield
N/A
% Institutions
60.09%
% Insiders
23.25%

1 Year

-30.1%

3 Year

-93.3%

10 Year

-93.3%
Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Company Information

Company Name
Neumora Therapeutics, Inc.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US6409791000
CIK: 0001885522
CUSIP: 640979100
Currency: USD
Full Time Employees: 63
Phone: 857 760 0900
Fiscal Year End: December
IPO Date: Sep 14, 2023
Description:

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-861 and NMRA-898, a M4 muscarinic receptor positive allosteric modulators (PAMs) for schizophrenia and other neuropsychiatric disorders. In addition, the company's preclinical phase product includes NMRA-GCase, an activator program for the treatment of Parkinson's Disease; NMRA-CK1d, a casein kinase 1 isoform delta (CK1d) inhibitor program for Amyotrophic Lateral Sclerosis; and NMRA-215 a brain-penetrant oral NLRP3 inhibitor for the treatment of obesity. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Address:

260 Arsenal Place, Watertown, MA, United States, 02472

People

Directors & Officers

Name Title Year Born
Mr. Paul L. Berns Executive Chairman 1967
Dr. Joshua Pinto Ph.D. President, CEO & Director 1985
Dr. Daljit Singh Aurora Pharm.D. Chief Operationg & Development officer 1968
Mr. Michael Lee Milligan CFO & Principal Accounting Officer 1973
Dr. Nicholas Brandon Ph.D. Chief Scientific Officer 1975
Mr. Pablo Gersberg Chief Information Officer NA
Mr. Jason G. Duncan J.D. Chief Legal & Administrative Officer 1974
Helen Rubinstein Head of Investor Relations NA
Ms. Amy Sullivan Chief Human Resources Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Feb 17, 2026 Daljit Singh Aurora N/A Sale 6.17K $3.56 $21.95K
Feb 17, 2026 Joshua Pinto N/A Sale 5.97K $3.54 $21.12K
Feb 17, 2026 Michael Lee Milligan N/A Sale 1.44K $3.56 $5.11K
Feb 17, 2026 Paul L Berns N/A Sale 9.82K $3.51 $34.46K
Nov 11, 2025 Daljit Singh Aurora N/A Sale 114.70K $2.68 $307.40K
Oct 27, 2025 Arch Venture Partners Xii, Llc N/A Purchase 1.92M $2.61 $5.00M
Oct 27, 2025 Kristina Burow N/A Purchase 1.92M $2.61 $5.00M

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
Siren, L.L.C. 8.50M Mar 31, 2026 4.52% $0.46 35.13%
SoftBank Group Corp 6.09M Jun 30, 2026 3.24% $0.06 0.00%
Perceptive Advisors LLC 5.10M Mar 31, 2026 2.72% $0.19 0.00%
MIC Capital Management UK LLP 4.46M Jun 30, 2026 2.37% $1.92 0.00%
Vanguard Capital Management, LLC 3.89M Mar 31, 2026 2.07% $0.00 0.00%
FMR Inc 3.50M Mar 31, 2026 1.86% $0.00 0.01%
Wellcome Trust Ltd 3.31M Jun 30, 2026 1.76% $0.06 0.00%
ICONIQ Capital, LLC 2.56M Jun 30, 2026 1.36% $0.13 0.00%
Lunate Capital Ltd 2.12M Jun 30, 2026 1.13% $1.84 0.00%
BlackRock Inc 2.05M Mar 31, 2026 1.09% $0.00 1.45%
Two Sigma Investments LLC 2.04M Mar 31, 2026 1.08% $0.00 55.75%
Johnson & Johnson 1.85M Jun 30, 2026 0.98% $0.39 0.00%
Renaissance Technologies Corp 1.39M Mar 31, 2026 0.74% $0.00 -3.94%
Ikarian Capital, LLC 1.28M Mar 31, 2026 0.68% $0.20 0.00%
Susquehanna International Group, LLP 1.24M Mar 31, 2026 0.66% $0.00 67.99%
Marshall Wace Asset Management Ltd 1.20M Mar 31, 2026 0.64% $0.00 104.76%
Geode Capital Management, LLC 1.09M Mar 31, 2026 0.58% $0.00 8.28%
SILVERARC CAPITAL MANAGEMENT, LLC 818.16K Mar 31, 2026 0.44% $0.16 0.00%
Tudor Investment Corp Et AL 771.42K Mar 31, 2026 0.41% $0.00 0.00%
Jane Street Group LLC 747.67K Mar 31, 2026 0.40% $0.00 -33.77%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 3.44M 1.83% ▲ 0.00% Jul 31, 2026
2 iShares Russell 2000 ETF 2.47M 1.31% ▼ 0.57% Aug 31, 2026
3 Vanguard Institutional Extnd Mkt Idx Tr 1.13M 0.60% ▲ 0.00% Jul 31, 2026
4 Fidelity Small Cap Index 1.12M 0.60% ▲ 0.00% Jun 30, 2026
5 iShares Russell 2000 Growth ETF 878.70K 0.47% ▲ 0.00% Aug 31, 2026
6 Russell 2000 Index Non-Lendable Fund 664.04K 0.35% ▲ 0.00% Jun 30, 2026
7 Russell 2000 Equity Index Fund B 664.04K 0.35% ▲ 0.00% Jun 30, 2026
8 Vanguard Russell 2000 ETF 577.87K 0.31% ▼ 2.59% Jul 31, 2026
9 iShares Biotechnology ETF 574.29K 0.31% ▲ 0.80% Aug 31, 2026
10 State St Russell Sm/Mid Cp® Indx SL Cl I 500.00K 0.27% ▲ 0.00% Jul 31, 2026

Financial Highlights

Market Cap: $214.20M
EBITDA: $-206.19M
Book Value: $0.24
Earnings/Share: $-1.17
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -73.85%
ROE (TTM): -187.11%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $161.89M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 187.90M
Shares Float: 116.36M
% Insiders: 23.25%
% Institutions: 60.09%
Short % Float: 7.27%

Stock Price History

1 Year Price History

3 Years Price History

10 Years Price History

Financial Charts

Revenue, Net Income & Operating Cash Flow (Yearly)

Revenue, Net Income & Operating Cash Flow (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-5.00M
Gross Profit
subtotal
$-5.00M
SG&A
adjust
$-60.09M
R&D
adjust
$-176.07M
Operating Income
subtotal
$-241.16M
Other / Non-Operating Items
adjust
$4.23M
Net Income
subtotal
$-236.93M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about NMRA.US!